| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:2955.)
© 2003 American Heart Association, Inc.
Basic Science Reports |
From the Angiogenesis Laboratory (S.S., R.-C.L., T.-P.D.F.), Glaxo Institute of Applied Pharmacology (L.A.S.), Department of Pharmacology; Department of Oncology (E.G.), University of Cambridge, Cambridge, United Kingdom; and the Biological Engineering Division, M.I.T (S.S., G.Z., R.S.), Whitehead Institute (N.W.), Cambridge, Mass.
Correspondence to Dr Shiladitya Sengupta, Biological Engineering Division, 16-561, Massachusetts Institute of Technology, 77, Massachusetts Ave, Cambridge, MA 02139. E-mail shiladit{at}MIT.edu
Background Hepatocyte growth factor/scatter factor (HGF/SF) can sufficiently and independently induce pathophysiological angiogenesis. However, the treatment strategies have mostly been unsuccessful. The present study is the first to evaluate the possible targeting of downstream signals for the inhibition of HGF/SF-induced angiogenesis.
Methods and Results In a multichannel scratch assay with human endothelial cells (ECs), HGF/SF induced a strong and prolonged activation of MAPK and cell proliferation that was inhibited by PD98059 and LY294002/wortmannin, selective inhibitors of MAPK and PI3K signaling modules, respectively. Western blotting demonstrated a temporal relation between the activation of the two pathways. Chemical inhibition of the PI3K and MAPK signals inhibited HGF/SF-induced chemoinvasion of ECs in vitro and blocked the HGF/SF-induced neovascularization into a polymer scaffold in vivo, as quantified by vessel counts and the clearance of radioactive 133Xe.
Conclusions These data indicate that MEK and PI3K inhibitors represent a promising approach to the clinical management of pathological conditions characterized by overt HGF/SF-induced angiogenesis.
Key Words: angiogenesis growth substances endothelium signal transduction
This article has been cited by other articles:
![]() |
S. Basu, R. Harfouche, S. Soni, G. Chimote, R. A. Mashelkar, and S. Sengupta Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy PNAS, May 12, 2009; 106(19): 7957 - 7961. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. McKinnon, E. Gherardi, M. Reidy, and D. Bowyer Hepatocyte Growth Factor/Scatter Factor and MET Are Involved in Arterial Repair and Atherogenesis Am. J. Pathol., January 1, 2006; 168(1): 340 - 348. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sengupta, S.-A. Toh, L. A. Sellers, J. N. Skepper, P. Koolwijk, H. W. Leung, H.-W. Yeung, R. N.S. Wong, R. Sasisekharan, and T.-P. D. Fan Modulating Angiogenesis: The Yin and the Yang in Ginseng Circulation, September 7, 2004; 110(10): 1219 - 1225. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sengupta, L. A. Sellers, T. Cindrova, J. Skepper, E. Gherardi, R. Sasisekharan, and T.-P. D. Fan Cyclooxygenase-2-selective Nonsteroidal Anti-Inflammatory Drugs Inhibit Hepatocyte Growth Factor/Scatter Factor-induced Angiogenesis Cancer Res., December 1, 2003; 63(23): 8351 - 8359. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |